Community-acquired bacterial pneumonia
Conditions
Interventions
1) Levofloxacin (500 mg) is administered orally or intravenously (over approximately 60 minutes) once daily. The administration route can be switched from intravenous to oral during the treatment peri
= Ccr <
50mL/min :500 mg initial dose, then 250 mg every 24 hours. Ccr <
20mL/min :500 mg initial dose, then 250 mg every 48 hours.
Sponsors
Nagasaki evaluation organization for clinical interventions
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who the investigator judges to be suitable for treatment with antibacterial drugs. 2) Acute infiltrative changes are detected by chest X-ray or CT within the previous 48 hours and the investigator suspects community-acquired pneumonia from observation including at least one of the clinical symptoms/findings listed below: - Cough - Purulent sputum or increased purulence of sputum. - Abnormal findings on auscultation (including moist rales, dull breath sounds, and decreased breath sounds). - Dyspnea or/and tachypnea. - Fever (axillary temperature):37 degrees or more in temperature. - Increased white blood cell count (>10,000/mm3), stab leucocytes >15%, or decreased white blood cell count (<4,500/mm3). - Increase of CRP. - Hypoxemia
Exclusion criteria
Exclusion criteria: 1) Patients with bronchial obstruction or those who have a past history of obstructive pneumonia (excluding COPD patients). 2) Patients with primary lung cancer or those who have pulmonary metastasis. 3) Patients with cystic fibrosis, AIDS, pneumocystis pneumonia (including suspected pneumocystis pneumonia), or active pulmonary tuberculosis (including suspected active pulmonary tuberculosis). 4) Patients with suspected atypical pneumonia.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical response at the test-of-cure (TOC) visit. | — |
Countries
Japan
Contacts
Public ContactKatsunori Yanagihara
Nagasaki University Hospital Department of Laboratory Medicine
Outcome results
None listed